E-LIB Suche - Ergebnisse für: Hayden, Frederick G

1

Comparative Effectiveness of Baloxavir Marboxil and Oseltam..:

Ikematsu, Hideyuki ; Baba, Takamichi ; Saito, Masaya M....
Influenza and Other Respiratory Viruses. 18 (2024) 5 - p. , 2024

Link: https://doi.org/10.1111/..

2

Oral Favipiravir Exposure and Pharmacodynamic Effects in Ad..:

Hayden, Frederick G ; Lenk, Robert P ; Epstein, Carol.
The Journal of Infectious Diseases. , 2023

Link: https://doi.org/10.1093/..

3

Clinical and Economic Impact of COVID-19 on Agricultural Wo..:

Olson, Daniel ; Calvimontes, Diva M. ; Lamb, Molly M....
Emerging Infectious Diseases. 28 (2023) 13 - p. , 2023

Link: https://doi.org/10.3201/..

4

COVID-19, Influenza and RSV: Surveillance-informed preventi..:

McKimm-Breschkin, Jennifer L. ; Hay, Alan J. ; Cao, Bin...
Antiviral Research. 197 (2022) - p. 105227 , 2022

Link: https://doi.org/10.1016/..

5

Heterogeneity of treatment effect of interferon-β1b and lop..:

Arabi, Yaseen M. ; Asiri, Ayed Y. ; Assiri, Abdullah M....
Scientific Reports. 12 (2022) 1 - p. , 2022

Link: https://doi.org/10.1038/..

6

Favipiravir Treatment of Uncomplicated Influenza in Adults:..:

Hayden, Frederick G ; Lenk, Robert P ; Stonis, Lucille...
The Journal of Infectious Diseases. 226 (2022) 10 - p. 1790-1799 , 2022

Link: https://doi.org/10.1093/..

7

Reducing Influenza Virus Transmission: The Potential Value ..:

Hayden, Frederick G ; Asher, Jason ; Cowling, Benjamin J...
Clinical Infectious Diseases. 74 (2021) 3 - p. 532-540 , 2021

Link: https://doi.org/10.1093/..

8

Report of the National Institutes of Health SARS-CoV-2 Anti..:

Hall, Matthew D ; Anderson, James M ; Anderson, Annaliesa...
The Journal of Infectious Diseases. 224 (2021) Supplement_1 - p. S1-S21 , 2021

Link: https://doi.org/10.1093/..

9

Outcomes of Influenza with Treatment in Patients with Diabe..:

Ison, Michael G. ; de Cassia Castro, Rita ; Hurt, Aeron C....
Metabolism. 116 (2021) - p. 154624 , 2021

Link: https://doi.org/10.1016/..

10

Influenza polymerase inhibitor resistance: Assessment of th..:

Ison, Michael G. ; Hayden, Frederick G. ; Hay, Alan J....
Antiviral Research. 194 (2021) - p. 105158 , 2021

Link: https://doi.org/10.1016/..

11

Phase 2a, open-label, dose-escalating, multi-center pharmac..:

Wang, Yeming ; Zhong, Wu ; Salam, Alex...
eBioMedicine. 62 (2020) - p. 103125 , 2020

Link: https://doi.org/10.1016/..

12

Treatment of Middle East respiratory syndrome with a combin..:

and the Saudi Critical Care Trials group ; Arabi, Yaseen M. ; Asiri, Ayed Y....
Trials. 21 (2020) 1 - p. , 2020

Link: https://doi.org/10.1186/..

13

Comment to: Baloxavir efficacy in North American Adults:

Portsmouth, Simon ; Kawaguchi, Keiko ; Uehara, Takeki.
European Journal of Internal Medicine. 72 (2020) - p. 99-101 , 2020

Link: https://doi.org/10.1016/..

14

Respiratory Syncytial Virus Antivirals: Problems and Progre..:

Hayden, Frederick G ; Whitley, Richard J
The Journal of Infectious Diseases. 222 (2020) 9 - p. 1417-1421 , 2020

Link: https://doi.org/10.1093/..

15

Use of angiotensin-converting enzyme inhibitors and angiote..:

Xu, Jiuyang ; Huang, Chaolin ; Fan, Guohui...
Frontiers of Medicine. 14 (2020) 5 - p. 601-612 , 2020

Link: https://doi.org/10.1007/..